Drawing for BOSTON STRATEGICS

USPTO serial 86424109

BOSTON STRATEGICS

Reviewed by CopyMark Law Group

Reg. 4755189Status 710
Filing date
Status date
Registration date
Jun 16, 2015
Examiner
FRENCH, CURTIS W
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with BOSTON STRATEGICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Matthew D. Asbell

MATTHEW D. ASBELL LADAS & PARRY LLP1040 AVENUE OF THE AMERICASNEW YORK, NY 10018UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
035Business development services for global pharmaceutical companiesSECTION 8 - CANCELLED—
040Manufacturing services for others in the field of pharmaceutical preparations and medicinesSECTION 8 - CANCELLED—
042Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Pharmaceutical drug development services in the field of oncology drugs; Conducting clinical trials for others in the field of oncology; Laboratory research services relating to pharmaceutical preparations and medicines; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmologySECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 17, 2021C8..CANCELLED SEC. 8 (6-YR)—
Jun 16, 2020REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Aug 24, 2017CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Aug 24, 2017COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jun 16, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 31, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 31, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 11, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 26, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 26, 2015ALIEASSIGNED TO LIE—
Feb 6, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 6, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Feb 6, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 6, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 6, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 3, 2015DOCKASSIGNED TO EXAMINER—
Oct 23, 2014MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Oct 22, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 18, 2014NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance